Secukinumab is superior to ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial

被引：0
|
作者：
Bagel, J. [1 ]
Nia, J. [2 ]
Hashim, P. [2 ]
Patekar, M. [3 ]
de Vera, A. [3 ]
Hugot, S. [3 ]
Sheng, K. [4 ]
Xia, S. [5 ]
Gilloteau, I. [3 ]
Blauvelt, A. [6 ]
Lebwohl, M. [2 ]
Bian, M. [7 ]
机构：
[1] Psoriasis Treatment Ctr Cent New Jersey, East Windsor, NJ USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Novartis Beijing Novartis Pharma Co Ltd, Shanghai, Peoples R China
[6] Oregon Med Res Ctr, Portland, OR USA
[7] Novartis Pharmaceut Australia Pty Ltd, Macquarie Pk, NSW, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [1] Secukinumab is superior to ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial
    Bagel, Jerry
    Nia, John
    Hashim, Peter W.
    Patekar, Manmath
    Hugot, Sophie
    Sheng, Kuan
    Xia, Summer
    Gilloteau, Isabelle
    Blauvelt, Andrew
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB274 - AB274
  • [2] Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
    Thaci, Diamant
    Blauvelt, Andrew
    Reich, Kristian
    Tsai, Tsen-Fang
    Vanaclocha, Francisco
    Kingo, Kuelli
    Ziv, Michael
    Pinter, Andreas
    Hugot, Sophie
    You, Ruquan
    Milutinovic, Marina
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (03) : 400 - 409
  • [3] Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
    Jerry Bagel
    John Nia
    Peter W. Hashim
    Manmath Patekar
    Ana de Vera
    Sophie Hugot
    Kuan Sheng
    Summer Xia
    Isabelle Gilloteau
    Elisa Muscianisi
    Andrew Blauvelt
    Mark Lebwohl
    Dermatology and Therapy, 2018, 8 : 571 - 579
  • [4] Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
    Bagel, Jerry
    Nia, John
    Hashim, Peter W.
    Patekar, Manmath
    de Vera, Ana
    Hugot, Sophie
    Sheng, Kuan
    Xia, Summer
    Gilloteau, Isabelle
    Muscianisi, Elisa
    Blauvelt, Andrew
    Lebwohl, Mark
    DERMATOLOGY AND THERAPY, 2018, 8 (04) : 571 - 579
  • [5] Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)
    Bagel, J.
    Blauvelt, A.
    Nia, J.
    Hashim, P.
    Patekar, M.
    de Vera, A.
    Ahmad, K.
    Paguet, B.
    Xia, S.
    Muscianisi, E.
    Lebwohl, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (01) : 135 - 142
  • [6] Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
    Eyerich, Kilian
    Gottlieb, Alice B.
    Piaserico, Stefano
    Beissert, Stefan
    Gooderham, Melinda
    Kirby, Brian
    Tilt, Nicola
    Madden, Cynthia
    Wiegratz, Susanne
    de Cuyper, Dirk
    Elewski, Boni
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB22 - AB22
  • [7] Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
    Eyerich, Kilian
    Gottlieb, Alice B.
    Piaserico, Stefano
    Beissert, Stefan
    Gooderham, Melinda
    Kirby, Brian
    Tilt, Nicola
    Madden, Cynthia
    Wiegratz, Susanne
    de Cuyper, Dirk
    Merola, Joseph F.
    Elewski, Boni
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4467 - 4469
  • [8] Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
    Blauvelt, Andrew
    Reich, Kristian
    Tsai, Tsen-Fang
    Tyring, Stephen
    Vanaclocha, Francisco
    Kingo, Kulli
    Ziv, Michael
    Pinter, Andreas
    Vender, Ronald
    Hugot, Sophie
    You, Ruquan
    Milutinovic, Marina
    Thaci, Diamant
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (01) : 60 - +
  • [9] Ustekinumab improves quality of life in Japanese patients with moderate to severe plaque psoriasis
    Nakagawa, H.
    Kato, T.
    Kato, M.
    Igarashi, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 18 - 18
  • [10] Efalizumab for patients with moderate to severe plaque psoriasis - A randomized controlled trial
    Gordon, KB
    Papp, KA
    Hamilton, TK
    Walicke, PA
    Dummer, W
    Li, N
    Bresnahan, BW
    Menter, A
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (23): : 3073 - 3080
12345